[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645195":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":10,"enrollmentInfo":36,"targetDuration":10,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Multifocal or Multicentric Breast Cancer Patients Undergoing Breast-Conserving Surgery",null,"This cohort consists of female patients aged ≥18 years with pathologically confirmed unilateral multifocal or multicentric breast cancer who meet all inclusion and exclusion criteria. All participants receive standardized breast-conserving surgery combined with sentinel lymph node biopsy or axillary lymph node dissection as clinically indicated. Postoperatively, all subjects undergo standard adjuvant radiotherapy followed by individualized systemic adjuvant therapy (chemotherapy, endocrine therapy, anti-HER2 targeted therapy) formulated in accordance with national breast cancer clinical guidelines. No investigational interventions are administered, all treatments are routine standard clinical care. Participants will complete long-term follow-up for at least 3 years and finish validated patient-reported outcome (PRO) questionnaires at scheduled visits.",[13],"Other: Breast-conserving surgery, postoperative radiotherapy and individualized adjuvant systemic therapy",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Breast-conserving surgery, postoperative radiotherapy and individualized adjuvant systemic therapy","All patients receive routine standard clinical treatment rather than investigational interventions, including breast-conserving surgery, axillary staging surgery, postoperative adjuvant radiotherapy, and guideline-concordant chemotherapy, endocrine therapy or anti-HER2 targeted therapy according to pathological and molecular characteristics.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"WenBin Zhou, Ph.D","CONTACT","025-68308161","Zhouwenbin@njmu.edu.cn",{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100645195","safety-of-breast-conserving-surgery-for-multifocal-or-multicentric-breast-cancer-100645195",false,"NCT07677956","Safety of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer","Safety Evaluation of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Female patients aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n2. Pathologically confirmed invasive breast carcinoma or ductal carcinoma in situ (DCIS);\n3. Radiologically confirmed unilateral multifocal or multicentric breast cancer;\n4. No systemic distant metastasis detected on preoperative imaging;\n5. Comprehensive clinical evaluation predicts all tumor lesions can be completely resected by breast-conserving surgery (BCS) to obtain negative surgical margins, and patients are suitable for standardized adjuvant whole-breast radiotherapy postoperatively;\n6. Adequate function of vital organs (cardiac, hepatic, renal and hematopoietic systems) to tolerate surgery, subsequent adjuvant radiotherapy and chemotherapy;\n7. Voluntarily agree to participate in the study after fully understanding the study purpose, procedures, potential risks and benefits, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Inflammatory breast cancer;\n2. Extensive tumor burden that prevents complete resection via breast-conserving surgery or attainment of negative surgical margins;\n3. Severe dysfunction or failure of vital organs (heart, liver, kidney, lung) making patients unable to tolerate surgery, radiotherapy or chemotherapy;\n4. Pregnant or lactating women who are ineligible for postoperative radiotherapy;\n5. Patients who are unwilling or unable to complete long-term postoperative follow-up and data collection.","FEMALE","18 Years",{"count":37,"type":38},100,"ESTIMATED","OBSERVATIONAL","The objective of this observational study is to evaluate the oncological safety of breast-conserving surgery combined with standard postoperative radiotherapy in adult female patients diagnosed with multifocal or multicentric breast cancer. The main questions it aims to answer are:\n\nWhat is the local recurrence rate and the time distribution of local recurrence after breast-conserving therapy in patients with multifocal or multicentric breast cancer? What independent risk factors are associated with postoperative local recurrence among these patients? There is no separate comparison group in this single-arm prospective cohort study.\n\nParticipants will:\n\nReceive standardized breast-conserving surgery plus routine postoperative radiotherapy and individualized adjuvant therapy in accordance with clinical guidelines; Complete regular clinical follow-up visits, telephone and WeChat follow-ups for at least 3 years after surgery to collect data on surgical complications, tumor recurrence, metastasis and survival status; Fill out standardized questionnaires including Breast-Q, SDS, SAS and EORTC QLQ-C30 to assess postoperative breast satisfaction, psychological status and quality of life.",[42],"Breast Cancer",[44,45,46],"Multifocal or multicentric breast cancer","Breast-conserving surgery","Local recurrence","NOT_YET_RECRUITING","2026-06-30",{"date":50,"type":51},"2026-07-01","ACTUAL",{"date":53,"type":38},"2026-07-15",{"date":55,"type":38},"2036-12-30",{"name":5,"class":6}]